Refining sorafenib therapy

Lessons from clinical practice

Luigi Bolondi, Antonio Craxi, Franco Trevisani, Bruno Daniele, Giovan Giuseppe Di Costanzo, Stefano Fagiuoli, Calogero Cammà, Paolo Bruzzi, Romano Danesi, Federico Spandonaro, Corrado Boni, Armando Santoro, Massimo Colombo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symptomatic progression should also be considered. If second-line therapies or trials are unavailable, continuing sorafenib beyond radiologic progression may provide a clinical benefit. Our recommendations enable the maximization of treatment duration, and hence clinical benefit, for patients.

Original languageEnglish
Pages (from-to)449-465
Number of pages17
JournalFuture Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Therapeutics
Hepatocellular Carcinoma
sorafenib
Neoplasms

Keywords

  • adverse event management
  • Child-Pugh B
  • dose modification
  • elderly
  • hepatocellular carcinoma
  • mRECIST
  • postprogression treatment
  • real-world data
  • response assessment
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Bolondi, L., Craxi, A., Trevisani, F., Daniele, B., Di Costanzo, G. G., Fagiuoli, S., ... Colombo, M. (2015). Refining sorafenib therapy: Lessons from clinical practice. Future Oncology, 11(3), 449-465. https://doi.org/10.2217/fon.14.261

Refining sorafenib therapy : Lessons from clinical practice. / Bolondi, Luigi; Craxi, Antonio; Trevisani, Franco; Daniele, Bruno; Di Costanzo, Giovan Giuseppe; Fagiuoli, Stefano; Cammà, Calogero; Bruzzi, Paolo; Danesi, Romano; Spandonaro, Federico; Boni, Corrado; Santoro, Armando; Colombo, Massimo.

In: Future Oncology, Vol. 11, No. 3, 01.02.2015, p. 449-465.

Research output: Contribution to journalArticle

Bolondi, L, Craxi, A, Trevisani, F, Daniele, B, Di Costanzo, GG, Fagiuoli, S, Cammà, C, Bruzzi, P, Danesi, R, Spandonaro, F, Boni, C, Santoro, A & Colombo, M 2015, 'Refining sorafenib therapy: Lessons from clinical practice', Future Oncology, vol. 11, no. 3, pp. 449-465. https://doi.org/10.2217/fon.14.261
Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S et al. Refining sorafenib therapy: Lessons from clinical practice. Future Oncology. 2015 Feb 1;11(3):449-465. https://doi.org/10.2217/fon.14.261
Bolondi, Luigi ; Craxi, Antonio ; Trevisani, Franco ; Daniele, Bruno ; Di Costanzo, Giovan Giuseppe ; Fagiuoli, Stefano ; Cammà, Calogero ; Bruzzi, Paolo ; Danesi, Romano ; Spandonaro, Federico ; Boni, Corrado ; Santoro, Armando ; Colombo, Massimo. / Refining sorafenib therapy : Lessons from clinical practice. In: Future Oncology. 2015 ; Vol. 11, No. 3. pp. 449-465.
@article{19d753481d29475fab0af74980d0dbbf,
title = "Refining sorafenib therapy: Lessons from clinical practice",
abstract = "Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symptomatic progression should also be considered. If second-line therapies or trials are unavailable, continuing sorafenib beyond radiologic progression may provide a clinical benefit. Our recommendations enable the maximization of treatment duration, and hence clinical benefit, for patients.",
keywords = "adverse event management, Child-Pugh B, dose modification, elderly, hepatocellular carcinoma, mRECIST, postprogression treatment, real-world data, response assessment, sorafenib",
author = "Luigi Bolondi and Antonio Craxi and Franco Trevisani and Bruno Daniele and {Di Costanzo}, {Giovan Giuseppe} and Stefano Fagiuoli and Calogero Camm{\`a} and Paolo Bruzzi and Romano Danesi and Federico Spandonaro and Corrado Boni and Armando Santoro and Massimo Colombo",
year = "2015",
month = "2",
day = "1",
doi = "10.2217/fon.14.261",
language = "English",
volume = "11",
pages = "449--465",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Refining sorafenib therapy

T2 - Lessons from clinical practice

AU - Bolondi, Luigi

AU - Craxi, Antonio

AU - Trevisani, Franco

AU - Daniele, Bruno

AU - Di Costanzo, Giovan Giuseppe

AU - Fagiuoli, Stefano

AU - Cammà, Calogero

AU - Bruzzi, Paolo

AU - Danesi, Romano

AU - Spandonaro, Federico

AU - Boni, Corrado

AU - Santoro, Armando

AU - Colombo, Massimo

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symptomatic progression should also be considered. If second-line therapies or trials are unavailable, continuing sorafenib beyond radiologic progression may provide a clinical benefit. Our recommendations enable the maximization of treatment duration, and hence clinical benefit, for patients.

AB - Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symptomatic progression should also be considered. If second-line therapies or trials are unavailable, continuing sorafenib beyond radiologic progression may provide a clinical benefit. Our recommendations enable the maximization of treatment duration, and hence clinical benefit, for patients.

KW - adverse event management

KW - Child-Pugh B

KW - dose modification

KW - elderly

KW - hepatocellular carcinoma

KW - mRECIST

KW - postprogression treatment

KW - real-world data

KW - response assessment

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84923082694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923082694&partnerID=8YFLogxK

U2 - 10.2217/fon.14.261

DO - 10.2217/fon.14.261

M3 - Article

VL - 11

SP - 449

EP - 465

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -